Approval

Approval  ·  Weekly Digest 10 May to 16 May 2025
RemeGen’s Disitamab vedotin gains approval in China for its third indication making it the first ADC approved for HER2-positive advanced Breast cancer with liver metastasis globally

Weekly Digest – May 2025 Weekly Digest – May 2025 09 May 2025: RemeGen’s Disitamab vedotin gains approval in China for its third indication making it the first ADC approved for HER2-positive advanced Breast cancer with liver metastasis globally China’s […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest 10 May to 16 May 2025
U.S. FDA Approves EMRELIS (Telisotuzumab vedotin-tllv) for adults with previously treated advanced Non-Small Cell Lung Cancer (NSCLC) with high c-Met protein overexpression

Weekly Digest – May 2025 Weekly Digest – May 2025 14 May 2025: U.S. FDA Approves EMRELIS (Telisotuzumab vedotin) for adults with previously treated advanced Non-Small Cell Lung Cancer (NSCLC) with high c-Met protein overexpression The FDA granted accelerated approval […]

by Sandhya Ramalingam

Continue Reading